ConductScience.org, home

Trial · NCT02420912

Adverse events231

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
otherAlanine aminotransferase increasedInvestigationsCohort I (Nivolumab, Ibrutinib) Chronic Lymphocytic Leukemia (CLL)171
otherAlanine aminotransferase increasedInvestigationsCohort II (Nivolumab, Previous Ibrutinib) Chronic Lymphocytic Leukemia (CLL)030
otherAlanine aminotransferase increasedInvestigationsCohort III (Nivolumab, Ibrutinib) Richters Transformation (RT)0260
otherAcute Otitis MediaEar and labyrinth disordersCohort I (Nivolumab, Ibrutinib) Chronic Lymphocytic Leukemia (CLL)070
otherAcute Otitis MediaEar and labyrinth disordersCohort II (Nivolumab, Previous Ibrutinib) Chronic Lymphocytic Leukemia (CLL)030
otherAcute Otitis MediaEar and labyrinth disordersCohort III (Nivolumab, Ibrutinib) Richters Transformation (RT)2262
otherAllergic rhinitisRespiratory, thoracic and mediastinal disordersCohort I (Nivolumab, Ibrutinib) Chronic Lymphocytic Leukemia (CLL)171
otherAllergic rhinitisRespiratory, thoracic and mediastinal disordersCohort II (Nivolumab, Previous Ibrutinib) Chronic Lymphocytic Leukemia (CLL)131
otherAllergic rhinitisRespiratory, thoracic and mediastinal disordersCohort III (Nivolumab, Ibrutinib) Richters Transformation (RT)0260
otherAnorexiaGastrointestinal disordersCohort I (Nivolumab, Ibrutinib) Chronic Lymphocytic Leukemia (CLL)171
otherAnorexiaGastrointestinal disordersCohort II (Nivolumab, Previous Ibrutinib) Chronic Lymphocytic Leukemia (CLL)131
otherAnorexiaGastrointestinal disordersCohort III (Nivolumab, Ibrutinib) Richters Transformation (RT)0260
otherAnxietyPsychiatric disordersCohort I (Nivolumab, Ibrutinib) Chronic Lymphocytic Leukemia (CLL)272
otherAnxietyPsychiatric disordersCohort II (Nivolumab, Previous Ibrutinib) Chronic Lymphocytic Leukemia (CLL)030
otherAnxietyPsychiatric disordersCohort III (Nivolumab, Ibrutinib) Richters Transformation (RT)1261
otherArthralgiaMusculoskeletal and connective tissue disordersCohort I (Nivolumab, Ibrutinib) Chronic Lymphocytic Leukemia (CLL)577
otherArthralgiaMusculoskeletal and connective tissue disordersCohort II (Nivolumab, Previous Ibrutinib) Chronic Lymphocytic Leukemia (CLL)030
otherArthralgiaMusculoskeletal and connective tissue disordersCohort III (Nivolumab, Ibrutinib) Richters Transformation (RT)6266
otherArthritisMusculoskeletal and connective tissue disordersCohort I (Nivolumab, Ibrutinib) Chronic Lymphocytic Leukemia (CLL)273
otherArthritisMusculoskeletal and connective tissue disordersCohort II (Nivolumab, Previous Ibrutinib) Chronic Lymphocytic Leukemia (CLL)030

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02420912/events